Stabilised Ceretec

Stabilised Ceretec is a radiopharmaceutical used for diagnostic imaging procedures. It contains Technetium (99mTc) Exametazime, a radioactive tracer for nuclear medicine scans. This product supports detection of various conditions through imaging. Short-term use only under medical supervision.

Stabilised Ceretec is primarily used in nuclear medicine imaging to evaluate cerebral perfusion, detect areas of inflammation or infection, and assess blood flow patterns. It is commonly employed in brain scans and white blood cell labeling for identifying abscesses or other inflammatory processes. The radiopharmaceutical helps healthcare professionals visualize internal structures and functions.

After intravenous administration, Stabilised Ceretec distributes throughout the body and accumulates in target tissues. The radioactive signal emitted allows imaging equipment to capture detailed pictures of blood flow and tissue activity. Patients may experience mild discomfort at the injection site, and the effects are temporary, aligning with the short half-life of the tracer.

Stabilised Ceretec should only be handled and administered by trained medical professionals in controlled settings. Pregnant or breastfeeding individuals should avoid exposure due to radiation risks. Patients with known allergies to any component of the product should inform their healthcare provider. Proper shielding and safety protocols must be followed during preparation and administration.

No direct drug interactions are known, but patients should disclose all medications, supplements, and recent imaging procedures to their healthcare provider. Radiopharmaceuticals may interfere with certain diagnostic tests, so timing of procedures should be coordinated. Alcohol and specific foods do not typically interact but should be discussed with a medical professional before use.